These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 28367681)

  • 1. Do polymorphisms in MDR1 and CYP3A5 genes influence the risk of cytogenetic relapse in patients with chronic myeloid leukemia on imatinib therapy?
    Harivenkatesh N; Kumar L; Bakhshi S; Sharma A; Kabra M; Velpandian T; Gogia A; Shastri SS; Gupta YK
    Leuk Lymphoma; 2017 Sep; 58(9):1-9. PubMed ID: 28367681
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of MDR1 and CYP3A5 genetic polymorphisms on trough levels and therapeutic response of imatinib in newly diagnosed patients with chronic myeloid leukemia.
    Harivenkatesh N; Kumar L; Bakhshi S; Sharma A; Kabra M; Velpandian T; Gogia A; Shastri SS; Biswas NR; Gupta YK
    Pharmacol Res; 2017 Jun; 120():138-145. PubMed ID: 28330783
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Relation between single Nucleotide Polymorphisms of CYP3A5 Gene and MDR1 Gene Loci and Risk of CML Cytogenetic Relapse].
    Yang ZY; Zhang YS; Liang CX; Zhou ZJ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Dec; 26(6):1644-1648. PubMed ID: 30501698
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Effect of MDR1 and CYP3A5 gene polymorphisms on outcomes of patients receiving imatinib treatment for chronic myeloid leukemia].
    He Y; Zao X; Wei X
    Nan Fang Yi Ke Da Xue Xue Bao; 2018 Jan; 38(1):34-41. PubMed ID: 33177018
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of CYP3A5*3 and ABCB1 C3435T on clinical outcomes and trough plasma concentrations of imatinib in Nigerians with chronic myeloid leukaemia.
    Adeagbo BA; Bolaji OO; Olugbade TA; Durosinmi MA; Bolarinwa RA; Masimirembwa C
    J Clin Pharm Ther; 2016 Oct; 41(5):546-51. PubMed ID: 27426203
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapy.
    Angelini S; Soverini S; Ravegnini G; Barnett M; Turrini E; Thornquist M; Pane F; Hughes TP; White DL; Radich J; Kim DW; Saglio G; Cilloni D; Iacobucci I; Perini G; Woodman R; Cantelli-Forti G; Baccarani M; Hrelia P; Martinelli G
    Haematologica; 2013 Feb; 98(2):193-200. PubMed ID: 22875622
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical relevance of a pharmacogenetic approach using multiple candidate genes to predict response and resistance to imatinib therapy in chronic myeloid leukemia.
    Kim DH; Sriharsha L; Xu W; Kamel-Reid S; Liu X; Siminovitch K; Messner HA; Lipton JH
    Clin Cancer Res; 2009 Jul; 15(14):4750-8. PubMed ID: 19584153
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of MDR1 gene polymorphism (G2677T) with imatinib response in Egyptian chronic myeloid leukemia patients.
    Elghannam DM; Ibrahim L; Ebrahim MA; Azmy E; Hakem H
    Hematology; 2014 Apr; 19(3):123-8. PubMed ID: 23683876
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Do SLCO1B3 (T334G) and CYP3A5*3 polymorphisms affect response in Egyptian chronic myeloid leukemia patients receiving imatinib therapy?
    Bedewy AM; El-Maghraby SM
    Hematology; 2013 Jul; 18(4):211-6. PubMed ID: 23394475
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of genetic polymorphisms on imatinib concentration and therapeutic response in patients with chronic-phase chronic myeloid leukemia.
    Cheng F; Cui Z; Li Q; Chen S; Li W; Zhang Y
    Int Immunopharmacol; 2024 May; 133():112090. PubMed ID: 38640718
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular study of ABCB1 gene and its correlation with imatinib response in chronic myeloid leukemia.
    Ben Hassine I; Gharbi H; Soltani I; Ben Hadj Othman H; Farrah A; Amouri H; Teber M; Ghedira H; Ben Youssef Y; Safra I; Abbes S; Menif S
    Cancer Chemother Pharmacol; 2017 Oct; 80(4):829-839. PubMed ID: 28836054
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multidrug resistance gene (MDR1) polymorphisms correlate with imatinib response in chronic myeloid leukemia.
    Ni LN; Li JY; Miao KR; Qiao C; Zhang SJ; Qiu HR; Qian SX
    Med Oncol; 2011 Mar; 28(1):265-9. PubMed ID: 20204543
    [TBL] [Abstract][Full Text] [Related]  

  • 13. C1236T polymorphism in MDR1 gene correlates with therapeutic response to imatinib mesylate in Indian patients with chronic myeloid leukaemia.
    Chhikara S; Sazawal S; Mishra P; Chaubey R; Mahapatra M; Saxena R
    Natl Med J India; 2015; 28(6):272-5. PubMed ID: 27294449
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of enzyme and transporter polymorphisms on trough imatinib concentration and clinical response in chronic myeloid leukemia patients.
    Seong SJ; Lim M; Sohn SK; Moon JH; Oh SJ; Kim BS; Ryoo HM; Chung JS; Joo YD; Bang SM; Jung CW; Kim DH; Park SY; Yoon SS; Kim I; Lee HG; Won JH; Min YH; Cheong JW; Park JS; Eom KS; Hyun MS; Kim MK; Kim H; Park MR; Park J; Kim CS; Kim HJ; Kim YK; Park EK; Zang DY; Jo DY; Lee HW; Yoon YR
    Ann Oncol; 2013 Mar; 24(3):756-60. PubMed ID: 23117072
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MDR1 gene polymorphisms and imatinib response in chronic myeloid leukemia: a meta-analysis.
    Zu B; Li Y; Wang X; He D; Huang Z; Feng W
    Pharmacogenomics; 2014 Apr; 15(5):667-77. PubMed ID: 24798723
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia.
    Dulucq S; Bouchet S; Turcq B; Lippert E; Etienne G; Reiffers J; Molimard M; Krajinovic M; Mahon FX
    Blood; 2008 Sep; 112(5):2024-7. PubMed ID: 18524988
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Louati N; Turki F; Mnif H; Frikha R
    J Oncol Pharm Pract; 2022 Jan; 28(1):39-48. PubMed ID: 33565361
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polymorphisms in the human organic cation transporter and the multidrug resistance gene: correlation with imatinib levels and clinical course in patients with chronic myeloid leukemia.
    Vine J; Cohen SB; Ruchlemer R; Goldschmidt N; Levin M; Libster D; Gural A; Gatt ME; Lavie D; Ben-Yehuda D; Rund D
    Leuk Lymphoma; 2014 Nov; 55(11):2525-31. PubMed ID: 24524306
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of genotypes and haplotypes of multi-drug transporter genes ABCB1 and ABCG2 with clinical response to imatinib mesylate in chronic myeloid leukemia patients.
    Au A; Aziz Baba A; Goh AS; Wahid Fadilah SA; Teh A; Rosline H; Ankathil R
    Biomed Pharmacother; 2014 Apr; 68(3):343-9. PubMed ID: 24581936
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship between SLCO1B3 and ABCA3 polymorphisms and imatinib response in chronic myeloid leukemia patients.
    de Lima LT; Bueno CT; Vivona D; Hirata RD; Hirata MH; Hungria VT; Chiattone CS; Zanichelli MA; Chauffaille Mde L; Guerra-Shinohara EM
    Hematology; 2015 Apr; 20(3):137-42. PubMed ID: 25056761
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.